Cargando…

Assessment of death risk of breast cancer patients with joint frailty models

OBJECTIVES: To investigate the effects of risk factors on recurrence and death in breast cancer patients, taking into account the dependence between recurrence and death as well as the heterogeneity among individuals. The other aim of this study was to make predictions of death risks with a dynamic...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasin, Ozge, Dirican, Ahmet, Ankarali, Handan, Disci, Rian, Karanlik, Hasan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Saudi Medical Journal 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253835/
https://www.ncbi.nlm.nih.gov/pubmed/32373916
http://dx.doi.org/10.15537/smj.2020.5.25065
_version_ 1783539410549080064
author Pasin, Ozge
Dirican, Ahmet
Ankarali, Handan
Disci, Rian
Karanlik, Hasan
author_facet Pasin, Ozge
Dirican, Ahmet
Ankarali, Handan
Disci, Rian
Karanlik, Hasan
author_sort Pasin, Ozge
collection PubMed
description OBJECTIVES: To investigate the effects of risk factors on recurrence and death in breast cancer patients, taking into account the dependence between recurrence and death as well as the heterogeneity among individuals. The other aim of this study was to make predictions of death risks with a dynamic model that includes patient’s history and different horizons. METHODS: The data of 465 patients who had undergone surgery at the Istanbul University Oncology Institute, Istanbul, Turkey, between 2009 and 2016 were used. For data analysis in this retrospective study, the authors applied the joint frailty model, and the predictions were obtained using dynamic prediction methods that consider the patient’s history. The Brier score was used to evaluate the accuracy of the estimations. RESULTS: A positive relationship was found between recurrence and death, and heterogeneity was found among patients (p<0.001, p=1.008, p=2.945). The effects of Cerb-B2, tumor type, remaining lymph nodes, neoadjuvant chemotherapy, and surgery type were statistically significant for death and recurrence (p<0.05, relative risk [death, recurrence] = [2.5, 11.86], [2.065, 2.798], [1.852, 3.113], [4.211, 9.366], [1.521,1.991]). The Brier score values used in the evaluation of the predictions obtained by the dynamic prediction methods were found to be below 0.30. CONCLUSION: The use of joint frailty models is recommended for the detection of heterogeneity effects and dependence between recurrence and death. Through models in survival analysis, researchers can obtain more accurate parameter estimates. A significant variance of frailty indicates different death risks for the same characteristics.
format Online
Article
Text
id pubmed-7253835
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Saudi Medical Journal
record_format MEDLINE/PubMed
spelling pubmed-72538352021-03-05 Assessment of death risk of breast cancer patients with joint frailty models Pasin, Ozge Dirican, Ahmet Ankarali, Handan Disci, Rian Karanlik, Hasan Saudi Med J Original Article OBJECTIVES: To investigate the effects of risk factors on recurrence and death in breast cancer patients, taking into account the dependence between recurrence and death as well as the heterogeneity among individuals. The other aim of this study was to make predictions of death risks with a dynamic model that includes patient’s history and different horizons. METHODS: The data of 465 patients who had undergone surgery at the Istanbul University Oncology Institute, Istanbul, Turkey, between 2009 and 2016 were used. For data analysis in this retrospective study, the authors applied the joint frailty model, and the predictions were obtained using dynamic prediction methods that consider the patient’s history. The Brier score was used to evaluate the accuracy of the estimations. RESULTS: A positive relationship was found between recurrence and death, and heterogeneity was found among patients (p<0.001, p=1.008, p=2.945). The effects of Cerb-B2, tumor type, remaining lymph nodes, neoadjuvant chemotherapy, and surgery type were statistically significant for death and recurrence (p<0.05, relative risk [death, recurrence] = [2.5, 11.86], [2.065, 2.798], [1.852, 3.113], [4.211, 9.366], [1.521,1.991]). The Brier score values used in the evaluation of the predictions obtained by the dynamic prediction methods were found to be below 0.30. CONCLUSION: The use of joint frailty models is recommended for the detection of heterogeneity effects and dependence between recurrence and death. Through models in survival analysis, researchers can obtain more accurate parameter estimates. A significant variance of frailty indicates different death risks for the same characteristics. Saudi Medical Journal 2020-05 /pmc/articles/PMC7253835/ /pubmed/32373916 http://dx.doi.org/10.15537/smj.2020.5.25065 Text en Copyright: © Saudi Medical Journal http://creativecommons.org/licenses/by-nc This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Pasin, Ozge
Dirican, Ahmet
Ankarali, Handan
Disci, Rian
Karanlik, Hasan
Assessment of death risk of breast cancer patients with joint frailty models
title Assessment of death risk of breast cancer patients with joint frailty models
title_full Assessment of death risk of breast cancer patients with joint frailty models
title_fullStr Assessment of death risk of breast cancer patients with joint frailty models
title_full_unstemmed Assessment of death risk of breast cancer patients with joint frailty models
title_short Assessment of death risk of breast cancer patients with joint frailty models
title_sort assessment of death risk of breast cancer patients with joint frailty models
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253835/
https://www.ncbi.nlm.nih.gov/pubmed/32373916
http://dx.doi.org/10.15537/smj.2020.5.25065
work_keys_str_mv AT pasinozge assessmentofdeathriskofbreastcancerpatientswithjointfrailtymodels
AT diricanahmet assessmentofdeathriskofbreastcancerpatientswithjointfrailtymodels
AT ankaralihandan assessmentofdeathriskofbreastcancerpatientswithjointfrailtymodels
AT discirian assessmentofdeathriskofbreastcancerpatientswithjointfrailtymodels
AT karanlikhasan assessmentofdeathriskofbreastcancerpatientswithjointfrailtymodels